Pilot study reports liver marker gains in dogs on supplement

A new pilot study in Frontiers in Veterinary Science suggests that a multi-component liver support supplement may improve biochemical liver markers in dogs that have abnormal lab work, but no outward clinical signs. In the study, 17 client-owned dogs with asymptomatic elevation of liver parameters received Hepatiale Forte Advanced for eight weeks, and investigators reported statistically significant reductions in ALT, AST, ALP, total bilirubin, and serum bile acids, with no adverse effects observed during supplementation. (frontiersin.org)

The paper lands in a familiar but still unsettled area of companion-animal medicine. Hepatoprotective nutraceuticals, especially products containing milk thistle derivatives and related compounds, are commonly used in dogs with suspected liver disease or unexplained enzyme elevations. But expert guidance has long pointed out that, while preclinical rationale exists, the veterinary clinical evidence has been thin, and stronger placebo-controlled trials are still needed. The 2019 ACVIM consensus statement on chronic hepatitis in dogs noted that documentation of benefit for milk thistle derivatives remains equivocal, and earlier reviews similarly concluded that strong clinical evidence for common canine liver nutraceuticals has been lacking. (pmc.ncbi.nlm.nih.gov)

In this study, the supplement combined several ingredients often positioned as hepatoprotective or metabolically supportive: phospholipids, amino acids, betaine, and milk thistle extract. According to the Frontiers report, the most notable changes over the eight-week period were in liver-associated biochemical markers rather than broader chemistry values, with no adverse shifts in glucose, albumin, or total protein. The product evaluated was Hepatiale Forte Advanced, a commercial formulation marketed for dogs and cats, and related company materials describe it as containing betaine, arginine, glutamine, milk thistle-derived silymarin, phospholipids, and zinc. (frontiersin.org)

The study’s strengths are its real-world population of client-owned dogs and its focus on a common clinical scenario: incidental or asymptomatic liver enzyme elevation. Still, the limitations matter. This was a small pilot study, and the available report does not make it a definitive test of efficacy against standard care or placebo. That distinction is important in a supplement category where spontaneous fluctuation in liver values, case heterogeneity, and concurrent management can complicate interpretation. (frontiersin.org)

Outside this paper, the broader literature offers some biologic plausibility, but not a settled clinical answer. Reviews of milk thistle and silymarin in veterinary use describe antioxidant and membrane-stabilizing effects that could support hepatoprotection, and some smaller canine studies have reported improvements in liver-associated enzymes. At the same time, evidence reviews aimed at clinicians and pet parents continue to rate the support for milk thistle in dogs as limited, and veterinary references emphasize that nutraceuticals are not FDA-reviewed like approved drugs and should not be treated as stand-alone therapy for underlying liver disease. (pmc.ncbi.nlm.nih.gov)

Why it matters: For veterinary professionals, this study is useful less as a final answer and more as a signal. Mild or asymptomatic liver parameter elevations are common in practice, and pet parents often ask about supplements before a diagnosis is fully established or while monitoring is underway. This paper gives clinicians a bit more published data to discuss when considering adjunctive support, particularly for dogs without overt clinical signs. But it doesn’t remove the need for diagnostic workups, medication review, diet assessment, imaging when indicated, or serial monitoring. The practical takeaway is cautious optimism: the formulation may help improve lab markers in some dogs, but the evidence is not yet strong enough to define standard-of-care use across cases. (frontiersin.org)

There’s also a category-level implication for the veterinary nutrition and supplement market. Multi-ingredient liver products are widely available, yet comparative data between formulations are sparse, and ingredient lists can vary substantially. That means veterinarians still have to judge products based on formulation transparency, quality control, the specific clinical context, and whether the supplement is being used as an adjunct rather than a substitute for diagnosis and treatment. (vcahospitals.com)

What to watch: The next meaningful development would be a larger randomized, controlled trial with clearer case definitions, standardized concurrent care, and follow-up beyond eight weeks. Clinicians will also want to see whether improvements in biochemical markers correspond to better imaging findings, histopathology, quality of life, or long-term outcomes, not just cleaner lab panels. (frontiersin.org)